Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $553,200.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Elena Ridloff sold 12,000 shares of Kymera Therapeutics stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $46.10, for a total transaction of $553,200.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded up $3.40 during trading on Thursday, reaching $47.66. The company's stock had a trading volume of 1,323,190 shares, compared to its average volume of 608,365. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -20.37 and a beta of 2.07. Kymera Therapeutics, Inc. has a 12 month low of $19.45 and a 12 month high of $53.27. The firm has a 50 day moving average of $29.40 and a 200-day moving average of $35.71.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. During the same quarter in the prior year, the firm posted ($0.69) EPS. The firm's quarterly revenue was up 114.6% on a year-over-year basis. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. Northern Trust Corp raised its stake in Kymera Therapeutics by 14.0% during the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after buying an additional 53,658 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after buying an additional 20,346 shares in the last quarter. Millennium Management LLC lifted its position in shares of Kymera Therapeutics by 205.0% in the fourth quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after buying an additional 77,912 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Kymera Therapeutics by 7.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock valued at $1,163,000 after purchasing an additional 2,011 shares during the period. Finally, Victory Capital Management Inc. raised its position in Kymera Therapeutics by 174.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock valued at $801,000 after purchasing an additional 12,643 shares during the period.

Wall Street Analyst Weigh In

KYMR has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. upped their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday. Guggenheim reissued a "buy" rating and issued a $52.00 price target on shares of Kymera Therapeutics in a report on Monday, May 12th. Stifel Nicolaus started coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They set a "buy" rating and a $55.00 price objective on the stock. Finally, HC Wainwright raised their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Two research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $59.35.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.